CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Trial of Immune Checkpoint Inhibitor With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03406858
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:11.528381+00:00
Published At: 2022-11-15T00:00:00+00:00
Record Updated At: 2023-05-03
Results Posted At: 2022-11-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Castration Levels of Testosterone", "Castration-Resistant Prostate Carcinoma", "Prostate Carcinoma Metastatic in the Bone", "PSA Progression", "Stage IV Prostate Adenocarcinoma AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-05-03"
protocolSection.identificationModule.nctId: "NCT03406858"
protocolSection.identificationModule.officialTitle: "Phase II Trial of Immune Checkpoint Inhibitor With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-11-15"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.